SELLAS Life Sciences (SLS) Stock Hits All-Time High – Here’s What’s Driving it

TLDR

• SLS hit a fresh 52-week high of $11.06, trading up over 17% Thursday
• An 8-K filing revealed amended executive employment agreements, including lump-sum change-of-control payments and immediate equity vesting — moves investors often read as M&A prep
• The Phase 3 REGAL trial for AML immunotherapy Galinpepimut-S is at 78 of 80 required survival events, putting a readout very close
• Q1 adjusted loss per share came in at -$0.05, better than the -$0.07 analyst estimate; cash stands at $107.1 million
• RSI sits at 72.67, putting the stock in overbought territory

SELLAS Life Sciences Group (SLS) had a big Thursday. The stock surged more than 17% intraday, hitting a fresh 52-week high of $11.06 and trading around $10.78 at time of publication. That follows a 396% run over the past year.

SELLAS Life Sciences Group, Inc., SLS

The catalyst this time was an 8-K filing.

SELLAS amended executive employment and severance agreements for CEO Dr. Angelos Stergiou and CFO John Burns. The updated terms include lump-sum change-of-control payments and mandatory immediate equity vesting on qualifying termination.

In biotech, that kind of executive contract restructuring tends to get investors’ attention fast. It’s a setup that traders commonly associate with an incoming acquisition, merger, or strategic partnership.

The company has not commented on any deal.

Phase 3 Trial Nearing the Finish Line

The contract changes come at a particularly sensitive moment for SELLAS. Its pivotal Phase 3 REGAL trial — testing Galinpepimut-S (GPS), a WT1-targeting peptide immunotherapy for acute myeloid leukemia — is sitting at 78 of the 80 survival events required to unblind final data.

The company remains blinded to the outcome. But with just two events left before the data lock, a readout could come any day. That alone has kept SLS on traders’ watchlists.

The pipeline also includes GFH009, a selective CDK9 inhibitor, though GPS is clearly the near-term focus.

Financials and Technical Setup

On the numbers side, SELLAS posted a Q1 adjusted loss per share of -$0.05, beating the -$0.07 analyst estimate. Cash and equivalents stood at $107.1 million as of March 31, boosted by approximately $28.7 million raised from warrant exercises in April and May.

Technically, the stock is extended. SLS is trading roughly 27% above its 20-day moving average and about 164% above its 200-day moving average. The RSI reads 72.67 — overbought by standard measures.

Key resistance sits at $10.65. The former 52-week high of $9.51 now acts as the first support level on any pullback.

With a beta of 2.53, volatility is part of the deal here. There are 196,632,574 common shares outstanding, and the market cap sits around $1.76 billion.

SLS was up 17.56% at $10.78 at time of publication Thursday.

The post SELLAS Life Sciences (SLS) Stock Hits All-Time High – Here’s What’s Driving it appeared first on CoinCentral.